News & Updates

Treating seizures with intravenous lacosamide appears to be safe and is associated with low rates of adverse events among critically ill children and neonates, as reported in a study.

A double-blind randomized controlled trial (RCT) finds that donepezil offers greater benefit in mild cognitive impairment (MCI) among individuals with hippocampal-sparing or minimal atrophy subtype vs individuals with typical or limbic-predominant patterns of atrophy.

Certain older adults with epilepsy have worse 24-hour memory retention, particularly those with greater frequency of interictal epileptiform activity (IEA), reduced slow wave activity (SWA) power during nonrapid eye movement (non-REM) sleep, and higher burden of antiseizure medications, according to a study.

A treatment strategy of targeting a low-density lipoprotein cholesterol (LDL-C) of <70 mg/dL leads to a significant reduction in the composite of adverse cardiovascular (CV) events in patients who have had stroke as compared with an LDL-C target of 100 mg/dL, according to data from the Treat Stroke to Target (TST) trial.

New drug applications approved by US FDA as of 16-30 June 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Progression to cognitive frailty may be predicted by factors including vision, high-density lipoprotein cholesterol (HDL-C) levels, education levels, and participation in cognitively stimulating activities, according to a Singapore study.